#Israel #Caesarea #IceCure Medical #ProSense #Shay Levav

IceCure Medical Promotes Shay Levav to Chief Operating Officer

IceCure Medical Ltd. (NASDAQ: ICCM), a pioneering entity in the field of minimally invasive cryoablation technology, has recently appointed Shay Levav as Chief Operating Officer (COO) in a strategic move anticipated to facilitate its growing commercial initiatives. The promotion of Levav comes at a critical juncture; following the recent FDA marketing authorization of ProSense®, a groundbreaking device designed for the treatment of low-risk breast cancer, the company aims to significantly bolster its operational framework as it expands its activities in the U.S. market.

A Milestone in Leadership

Shay Levav’s promotion integrates a robust leadership approach tailored for IceCure's ambitious commercial trajectory. Eyal Shamir, the CEO of IceCure, highlighted Levav's in-depth experience within the organization, noting his pivotal involvement in steering the ProSense® project through various clinical and regulatory stages since 2020. This accumulation of experience makes Levav an ideal candidate to oversee operational preparations as consumer interest in the ProSense® Cryoablation System continues to grow.

Levav’s role as COO will not only encompass overseeing the operational aspects related to FDA approval processes but will also contribute to enhancing quality assurance and clinical affairs, areas in which he has already demonstrated considerable acumen.

The ProSense® Cryoablation System

The ProSense® system is not just another device; it is the first of its kind to receive FDA clearance for local treatment of early-stage, low-risk breast cancer for older women, specifically those aged 70 and above. This innovative cryoablation technology employs the unique capability of liquid nitrogen to freeze tumors, providing a minimally invasive alternative to traditional surgical removal methods. The advantages of ProSense® extend beyond its innovative freezing technique; it significantly reduces patient recovery time, minimizes pain, and lessens the general risks associated with conventional operations.

With its transportable design, ProSense® caters to a wider range of treatment scenarios, facilitating efficient, office-based procedures that promise to enhance patient and provider accessibility and value alike.

Prospective Growth and Market Expansion

As IceCure looks forward to increasing its market penetration in the U.S. for ProSense®, Levav’s leadership is seen as crucial for solidifying and strengthening the firm's operational foundation. The company is poised for what is expected to be a substantial uptick in commercial momentum, bolstered by Shamir’s firm belief in Levav’s capabilities. Shamir stated, "We are expecting to experience growing commercial traction for ProSense® in the U.S., and Shay's leadership will be key in strengthening our operational foundation."

The upcoming period is described as a transformative phase for IceCure Medical as it endeavors to educate both healthcare professionals and the public about the potential benefits of ProSense®, thereby expanding its reach and ensuring widespread adoption of its innovative solutions.

A Look Ahead

Looking forward, IceCure Medical is committed to not only enhancing the visibility of ProSense® but also to maintaining its rigorous standards of innovation and safety while navigating the complexities of a deeply competitive healthcare landscape. The appointment of Shay Levav as COO is expected to play an integral part in this endeavor, ensuring IceCure remains at the forefront of cryoablation technology and its implementations in the treatment of cancerous growths across different types of malignancies, ranging from breast and kidney to lung and liver cancers.

Through this strategic promotion, IceCure Medical signals its readiness to meet the challenges of an evolving medical marketplace and its determination to redefine approaches to cancer treatment, prioritizing both effectiveness and patient comfort.